|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-4.75/-0.64
|
企業價值
1.27B
|
資產負債 |
每股賬面淨值
7.28
|
現金流量 |
現金流量率
--
|
損益表 |
收益
17.45M
|
每股收益
0.33
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/13 17:52 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |